On March 13, 2026, Bone Biologics Corporation filed an 8-K with the SEC announcing a prospectus supplement for an at-the-market offering program. The company plans to sell up to $1,064,000 of its common stock through H.C. Wainwright & Co., LLC as the sales agent. This offering follows a previous sale of approximately $1.7 million under a prior sales agreement. The funds raised are intended to support ongoing operations and growth initiatives.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.